Cargando…

Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice

The four serotypes of dengue virus (DENV1–4) continue to pose a major public health threat. The first licenced dengue vaccine, which expresses the surface proteins of DENV1–4, has performed poorly in immunologically naïve individuals, sensitising them to antibody-enhanced dengue disease. DENV non-st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilken, Lucas, Stelz, Sonja, Agac, Ayse, Sutter, Gerd, Prajeeth, Chittappen Kandiyil, Rimmelzwaan, Guus F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140942/ https://www.ncbi.nlm.nih.gov/pubmed/37112626 http://dx.doi.org/10.3390/vaccines11040714

Ejemplares similares

Transient Blockade of Type I Interferon Signalling Promotes Replication of Dengue Virus Strain D2Y98P in Adult Wild-Type Mice
por: Wilken, Lucas, et al.
Publicado: (2023)

A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
por: Kubinski, Mareike, et al.
Publicado: (2023)

Rift Valley Fever Virus—Infection, Pathogenesis and Host Immune Responses
por: Nair, Niranjana, et al.
Publicado: (2023)

Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice
por: Beicht, Jana, et al.
Publicado: (2023)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Altenburg, Arwen F., et al.
Publicado: (2017)

Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine
por: de Vries, Rory D., et al.
Publicado: (2015)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
por: Drexler, Ingo, et al.
Publicado: (2004)

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
por: Magnusson, Sofia E., et al.
Publicado: (2018)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development
por: Volz, A., et al.
Publicado: (2017)

Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?
por: Wilken, Lucas, et al.
Publicado: (2020)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
por: Kupke, Alexandra, et al.
Publicado: (2022)

Cross-reactive antibodies against Langat virus protect mice from lethal tick-borne encephalitis virus infection
por: Kubinski, Mareike, et al.
Publicado: (2023)

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines
por: Altenburg, Arwen F., et al.
Publicado: (2018)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells
por: Zimmerling, Stefan, et al.
Publicado: (2013)

Intact Type I Interferon Receptor Signaling Prevents Hepatocellular Necrosis but Not Encephalitis in a Dose-Dependent Manner in Rift Valley Fever Virus Infected Mice
por: Michaely, Lukas Mathias, et al.
Publicado: (2022)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Recombinant Modified Vaccinia Virus Ankara Expressing Glycoprotein E2 of Chikungunya Virus Protects AG129 Mice against Lethal Challenge
por: van den Doel, Petra, et al.
Publicado: (2014)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
por: Volz, Asisa, et al.
Publicado: (2018)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Host Responses to Respiratory Syncytial Virus Infection
por: Agac, Ayse, et al.
Publicado: (2023)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections
por: Meineke, Robert, et al.
Publicado: (2022)

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise
por: Kubinski, Mareike, et al.
Publicado: (2020)

FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants
por: Meineke, Robert, et al.
Publicado: (2023)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: López-Camacho, César, et al.
Publicado: (2019)

Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
por: Raadsen, Matthijs P, et al.
Publicado: (2023)

Immunity to TBEV Related Flaviviruses with Reduced Pathogenicity Protects Mice from Disease but Not from TBEV Entry into the CNS
por: Petry, Monique, et al.
Publicado: (2021)

Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens
por: Zanetti, Flavia Adriana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5edegj8o0cbit147q77iv15m20